Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
This study aims to collect prospective safety and effectiveness data for the C-Brace System, a microprocessor-controlled knee ankle foot orthosis, following standard care practices. The research focuses on patients with lower extremity pareses who are fitted with the C-Brace device. The goal is to better understand how the C-Brace influences walking speed, balance, risk of falling, and confidence in balance over time. The C-Brace is a custom-made device with thigh, calf, and foot components connected by an ankle joint or spring element. It uses sensors to continuously monitor knee joint movement and walking phases, adjusting hydraulic resistance and knee motion accordingly. Patients enrolled in the registry will undergo baseline evaluation, fitting, training or therapy sessions, and follow-up visits at 6, 12, 24, and 36 months after fitting. Participants will be assessed through various tests including timed walk tests, balance confidence scores, and mobility assessments at different intervals. The study also tracks falls related to device use and changes in activity levels with an activity tracker. Data collected will help characterize the safety and functional impact of the C-Brace over three years of follow-up.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
This trial investigates treatments for chronic lateral epicondylitis, also known as tennis elbow, which can cause pain and interfere with daily activities and work. The study aims to compare two treatment methods to determine if one is better than the other for relieving symptoms and improving function. It is a randomized controlled trial led by Sean Mc Millan, focusing on patients who have had symptoms for at least six months and have tried other treatments without success. Participants will be randomly assigned to receive either the Ultrasound-guided Percutaneous Tenotomy Technique Tenex procedure or Open Surgical Debridement. The Tenex procedure uses a special needle and ultrasonic energy to remove damaged tissue under local anesthesia in the surgeons office. Open Surgical Debridement is a traditional surgery involving an incision to remove damaged tissue under anesthesia in a surgery center. Both procedures target the damaged tendon area causing pain. During the study, participants will have follow-up visits at 3 weeks, 6 weeks, 3 months, 6 months, and 12 months after treatment. At each visit, their progress will be monitored through physical exams and questionnaires. The main outcome measured is the comparison of complications and functional results between the two treatments. The total participation period includes the initial screening and one year of follow-up to assess recovery and treatment effects.
Actively Recruiting
Researchers are evaluating whether adding stereotactic ablative radiotherapy SABR to the primary tumor along with standard immunotherapy improves outcomes for patients with metastatic, unresected renal cell carcinoma RCC that cannot be surgically removed. This phase II trial compares the combination of SABR plus immunotherapy to immunotherapy alone, focusing on progression-free survival and tumor response. The study also examines safety, response rates, surgery rates, survival, and explores biomarkers and effects on tumor spread. Participants are randomly assigned in a 21 ratio to either receive immunotherapy alone or immunotherapy combined with SABR. Immunotherapy regimens include various combinations of intravenous monoclonal antibodies nivolumab, ipilimumab, pembrolizumab, avelumab and oral antiangiogenic drugs axitinib, cabozantinib, lenvatinib, administered on schedules ranging from every 2 to 6 weeks. Those in the SABR group receive radiation therapy on three separate days over 1 to 3 weeks alongside their immunotherapy. Throughout treatment, patients undergo CT or MRI scans, possible bone scans, and blood sample collections. After treatment, participants are followed every six months for five years, then annually for three more years to monitor outcomes. The study measures nephrectomy and radiographic progression-free survival up to eight years, along with secondary outcomes like response rates, overall survival, treatment-free survival, and adverse events. Regular imaging and laboratory tests track disease status and treatment effects, supporting long-term safety and efficacy assessment.